All News

Top news of the day from across the health care landscape

Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.

What is causing this patient to lose her sense of smell?

Pharmacy Times® and Parata Systems, the founding partners of the Next-Generation Pharmacist® awards, honored the 2019 winners, named at the annual awards gala Friday, October 25, at the Hotel del Coronado in San Diego, California.

Ron Lanton III, Esq., discusses the specialty pharmacist's role in educating patients about biosimilars and biologics.

Mylan Pharmaceuticals Inc. is operating a voluntary nationwide recall of one lot of Alprazolam Tablets, USP C-IV 0.5 mg to the consumer/user level. This recall stems from the potential presence of foreign substance, and to date, Mylan has not received any adverse events related to this batch.

Wild Poliovirus Type 3 (WPV3) has been eradicated worldwide, according to the Global Polio Eradication Initiative, a branch of the World Health Organization.

Officials with the FDA have expanded the use of Melinta Therapeutics’ delafloxacin (Baxdela) to include treatment of adult patients with community-acquired bacterial pneumonia caused by designated susceptible bacteria, but the drug’s availability will be delayed for this new indication.

National Institutes of Health experts discuss optimization of existing strategies for HIV treatment and prevention, as well as the development of new approaches.

Top news of the week from Specialty Pharmacy Times.

All 50 states accept the ExCPT exam from National Healthcareer Association (NHA), helping more pharmacy technicians earn a national credential.

Researchers have found that patients with high blood pressure (BP) who take all their antihypertensive medications at bedtime have better controlled blood pressure and a significantly lower risk of death or illness caused by heart or blood vessel problems, compared to patients who take their medications in the morning.1

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

Ron Lanton III, Esq., discusses challenges in launching biosimilars after they've been approved.

Psoriasis may increase the risk of cancer incidence and cancer-related mortality in affected individuals.

Effective December 31, 2019, Amgen’s 60% annual list price cut for evolocumab (Repatha) will be fully implemented.

Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).

Officials from the FDA have cleared an investigational new drug (IND) application for BW-1010 (BlueWillow Biologics), according to the company. The drug would be the company’s next-generation anthrax vaccine candidate.

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.

The influenza A virus remains contagious in wet mucus from infected patients, even after being exposed to an ethanol-based disinfectant.

McKesson’s Health Mart has announced a partnership with Amazon Hub Counter pickup points, offering customers more convenient delivery options.

Top news of the day from across the health care landscape.

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

According to the 2018 National Survey on Drug Use and Health, 9.9 million Americans misused controlled prescription drugs. On October 26, 2019 health care organizations across the country are participating in National Prescription Drug Take Back Day to help address this public safety and public health issue.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.

Bemcentinib is being evaluated as a treatment for elderly patients with acute myeloid leukemia whose disease has relapsed.